PMID- 38001705
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231127
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 22
DP  - 2023 Nov 16
TI  - LCMR1 Promotes Large-Cell Lung Cancer Proliferation and Metastasis by 
      Downregulating HLA-Encoding Genes.
LID - 10.3390/cancers15225445 [doi]
LID - 5445
AB  - Lung cancer is notorious for its high global morbidity and mortality. Here, we 
      examined whether the LCMR1 gene, which we previously cloned from a human 
      large-cell lung carcinoma cell line, contributes to the proliferation and 
      metastasis of large-cell lung carcinoma. To this end, we performed pan-cancer and 
      non-small cell lung cancer (NSCLC) cell line-based LCMR1 expression profiling. 
      Results revealed that LCMR1 was expressed at high levels in most solid tumors, 
      including NSCLC. LCMR1 expression was the highest in the 95D large cell lung 
      cancer cell line. Functional studies using lentivirus-based knockdown revealed 
      that LCMR1 was critical for the proliferation, migration, and invasion of 
      cultured large cell lung cancer cells. Moreover, blocking this gene significantly 
      reduced tumor growth in a 95D cell xenograft mouse model. A multiple 
      sequence-based assay revealed a mechanism by which LCMR1 diminished the RNA Pol 
      II occupancy at the promoter of human leukocyte antigen (HLA)-encoding genes to 
      prevent their transcription. The HLA genes play vital roles in cancer-specific 
      antigen presentation and anticancer immunity. A correlation assay using TCGA 
      database identified a negative relationship between the expression levels of 
      LCMR1 and HLA coding genes. Taken together, our findings demonstrate that LCMR1 
      is required for large cell lung cancer cell growth and invasion and suggest its 
      potential as a valid target in clinical treatment.
FAU - Liu, Lu
AU  - Liu L
AD  - Medical School of Chinese PLA, Beijing 100853, China.
AD  - Department of Nutrition, The First Medical Center of Chinese PLA General 
      Hospital, Beijing 100853, China.
FAU - Li, Chunsun
AU  - Li C
AD  - Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Wu, Zhen
AU  - Wu Z
AD  - Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Li, Yanqin
AU  - Li Y
AD  - Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Yu, Hang
AU  - Yu H
AD  - Medical School of Chinese PLA, Beijing 100853, China.
AD  - Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Li, Tao
AU  - Li T
AUID- ORCID: 0000-0002-9038-4794
AD  - Medical School of Chinese PLA, Beijing 100853, China.
AD  - Department of Oncology, The First Medical Center of Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Wang, Yueming
AU  - Wang Y
AD  - Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, 
      Beijing 100853, China.
AD  - School of Medicine, Nankai University, Tianjin 300071, China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, 
      Beijing 100853, China.
FAU - Chen, Liangan
AU  - Chen L
AD  - Medical School of Chinese PLA, Beijing 100853, China.
AD  - Department of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, 
      Beijing 100853, China.
LA  - eng
GR  - 2020-1-5011/the Capital's Funds for Health (CFH)/
PT  - Journal Article
DEP - 20231116
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10670470
OTO - NOTNLM
OT  - LCMR1
OT  - NSCLC
OT  - human leukocyte antigen
OT  - migration
OT  - proliferation
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/25 12:43
MHDA- 2023/11/25 12:44
PMCR- 2023/11/16
CRDT- 2023/11/25 01:06
PHST- 2023/10/18 00:00 [received]
PHST- 2023/11/09 00:00 [revised]
PHST- 2023/11/13 00:00 [accepted]
PHST- 2023/11/25 12:44 [medline]
PHST- 2023/11/25 12:43 [pubmed]
PHST- 2023/11/25 01:06 [entrez]
PHST- 2023/11/16 00:00 [pmc-release]
AID - cancers15225445 [pii]
AID - cancers-15-05445 [pii]
AID - 10.3390/cancers15225445 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Nov 16;15(22):5445. doi: 10.3390/cancers15225445.